RUTHERFORD, N.J., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report third quarter 2014 financial results on Monday, November 10, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the third quarter financial results and to answer questions.
|Conference Call & Webcast|
|Monday, November 10, 2014 at 8:30 a.m. EST/5:30 a.m. PST|
|Replays – Available through November 24, 2014|
About Cancer Genetics
Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.
CONTACT: Investor Relations Andrew McDonald Life Science Advisors LLC 646-597-6987 Media Relations Paul Kuntz RedChip Companies, Inc. 800-733-2447, ext. 105 firstname.lastname@example.orgSource:Cancer Genetics